An observational study in Breast Cancer and Radiation Toxicity, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Completed. Open to female participants. Per ClinicalTrials.gov, last updated 2018-03-12.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
Among 12 studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 6 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Among the 12 studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is one of 2 that started in 2001, is one of 8 observational ones, and was the 2nd registered.
14,829 studies on the registry are indexed under Breast Neoplasms; 3,318 are open to participants now.
Browse Breast Neoplasms studies →6 of the 12 studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18–38 · Women only
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 20–70 · Women only
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+ · Women only
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,398 Breast Neoplasms studies recruiting now, 1,569 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2001.
This study's enrollment of 447 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Median enrollment 81 across the 4 interventional studies, 341 across the 8 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 513 studies on the registry; 288 are open to participants now.
2 of the studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02261389IRCCS Azienda Ospedaliero-Universitaria di BolognaFollow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET | 2026-11 |
| NCT06805084IRCCS Azienda Ospedaliero-Universitaria di BolognaTranscripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial was a retrospective study on postoperative accelerated hypofractionated IMRT (MARA-1) in patients with early stage breast carcinoma, to compare late toxicity after this treatment and standard fractionated RT delivered with 3D-CRT.
The aim of this study was to evaluate the clinical results in terms of late skin and subcutaneous toxicity of accelerated hypofractionated forward-planned IMRT in patients with early stage BC. Results were compared with a historical control group (CG) of patients treated with 3D-conformal postoperative RT delivered with conventional fractionation.
From 2003, all women fullfilling the inclusion criteria were treated with MARA-1 scheme
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A forward planned IMRT technique was used and the prescribed dose to the breast was 40 Gy in 16 fx with a concomitant boost of 4 Gy.
Radiation: accelerated hypofractionated RT
In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) delivered with 3D-RT, followed by a sequential boost on the tumour bed of 10 Gy in 4 fx delivered with electrons
Radiation: conventional fractionated RT
Incidence of treatment-related late adverse events
late toxicity (cutaneous and subcutaneous) is evaluated using RTOG/EORTC criteria in both groups of patients
Time frame: 5 years
Incidence of treatment-related acute adverse events
acute toxicity (cutaneous and subcutaneous) is evaluated using RTOG/EORTC criteria in both groups of patients
Time frame: 6 months
local control
absence of locoregional relapse
Time frame: 5 years
overall survival
defined as the time from diagnosis to death
Time frame: 5 years
No study locations are listed for this record.
Plan to share: No
Ran from Jan 2001 to primary completion in Dec 2017, 203 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna →